




What is claimed is:

1. A compound of formula (I):



or a pharmaceutically acceptable salt, ester, solvate, or stereoisomer thereof,
wherein:

-L- is defined as: $-(C_1-C_5)\text{alkylene-O-C(O)-}$, $-(C_3-C_5)\text{alkenylene-O-}$,



A is $-(C_1-C_5)\text{alkylene-O-C(O)-}$;

E is $-\text{O-}$, $-\text{O-C(O)N(H)-}$, $-\text{O-C(S)N(H)-}$ or $-\text{S-}$ or $-\text{S-C(O)N(H)-}$;

D is $-(C_1-C_5)\text{alkylene-}$ or $-(C_3-C_5)\text{alkenylene-}$;

Y^1 is C=C, carbon or nitrogen, wherein if Y^1 is nitrogen, Z^1 is absent;

Each of Y^4 and Y^5 is independently carbon or nitrogen, wherein if Y^3 is nitrogen, Z^3 is absent and if Y^4 is nitrogen, Z^5 is absent;

Y^2 is C or N;

Y⁵ is an oxygen, carbon, nitrogen or a sulfur atom, wherein Z⁶ is absent when Y⁵ is an oxygen, or a sulfur atom;

Each of Z¹, and Z², where present, are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkyloxy, alkenyloxy, alkynyloxy, aryloxy, aralkyloxy, alkylthioxy, alkenylthioxy, alkynylthioxy, arylthioxy, aralkylthioxy, amino, hydroxy, thio, halo, carboxy, formyl, nitro and cyano, wherein each alkyl, alkenyl, alkynyl, alkoxy, and aryl moiety is independently optionally substituted with 1-3 halo;

Z³, Z⁴, and Z⁵ are each independently selected from hydrogen, alkyl, deuterated alkyl, C₁₋₆alkoxy, deuterated C₁₋₆alkoxy, alkenyl, alkynyl, aryl, aralkyl, alkyloxy, alkenyloxy, alkynyloxy, aryloxy, aralkyloxy, alkylthioxy, alkenylthioxy, alkynylthioxy, arylthioxy, aralkylthioxy, amino, hydroxy, thio, halo, carboxy, formyl, nitro and cyano, wherein each alkyl, alkenyl, alkynyl, alkoxy, and aryl moiety is independently optionally substituted with 1-3 halo;

provided that at least one of Z¹, Z² or Z⁴ is H;

Z⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl and aralkyl, wherein each alkyl, alkenyl, alkynyl, alkoxy, and aryl moiety is independently optionally substituted with 1-3 halo;

Each Z⁸ is independently hydrogen, unsubstituted C_{1-C6} alkyl, substituted C_{1-C6} alkyl, unsubstituted C_{1-C6} alkoxy, unsubstituted deuterated C_{1-C6} alkoxy, substituted C_{1-C6} alkoxy, and substituted deuterated C_{1-C6} alkoxy where the substituted alkyl, alkoxy and deuterated alkoxy are substituted with one or more groups selected from amino, mono- or di-substituted amino, cyclic C_{1-C5} alkylamino, imidazolyl, C_{1-C6} alkylpiperazinyl, morpholino, thiol, thioether, tetrazole, carboxylic acid, ester, amido, mono- or di-substituted amido, N-connected amide, N-connected sulfonamide, sulfoxy, sulfonate, sulfonyl, sulfoxy, sulfinate, sufinyl, phosphonooxy, phosphate or sulfonamide, wherein each alkyl, alkenyl, alkynyl, alkoxy, and aryl is optionally substituted with 1-3 halo.


2. The compound, of claim 1, or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein Y³ and Y⁴ are each carbon.

3. The compound according to any of the above claims, or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein Z³, Z⁴ and Z⁵ are each selected from halo, unsubstituted C_{1-C3} alkyl, substituted C_{1-C3} alkyl, unsubstituted C_{1-C3} alkoxy, substituted C_{1-C3} alkoxy, unsubstituted deuterated C_{1-C3} alkoxy, or substituted C_{1-C3} alkoxy, wherein each alkyl and alkoxy moiety can be independently substituted with 1-3 halo.

4. The compound according to any of the above claims, or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein Z³, Z⁴ and Z⁵ are each selected from

bromo, chloro, fluoro, methyl, deuterated methyl optionally substituted with 1-3 halo, methoxy optionally substituted with 1-3 halo, or deuterated methoxy.


5. The compound according to any of the above claims having formula (Ia):















or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof,

wherein L, Y¹, Y², Y⁵, Z³, Z⁴, Z⁵, and Z⁶ are each as defined in any one of claims 1-4, and Effector is part of a (i) a phosphoric acid derivative of gemcitabine, or (ii) a salt form of a phosphoric acid derivative of gemcitabine.

6. The compound according to any of the above claims having formulae (Ib-i), (Ib-ii), (Ib-iii), (Ib-iv), (Ib-v), (Ib-vi), (Ib-vii), (Ib-viii), (Ib-ix), (Ib-x), (Ib-xi), (Ib-xii), (Ib-xiii), (Ib-xiv), (Ib-xv), (Ib-xvi), (Ib-xvii), or (Ib-xviii):






or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer of any of the above formulae, wherein:

Z³ and Z⁵ are each independently halo, methyl optionally substituted with 1-3 halo, methoxy optionally substituted with 1-3 halo or deuterated methoxy;

Z⁴, when present, is halo, methyl optionally substituted with 1-3 halo, methoxy optionally substituted with 1-3 halo or deuterated methoxy;

-L-Effector is: -(C₁-C₃)alkylene-O-C(O)-Effector,



D is -(C₁-C₃)alkylene-;

E is -O-, -O-C(O)N(H)-, -O-C(S)N(H)-, -S- or -S-C(O)N(H)-;











A is -(C₁-C₃)alkylene-O-C(O)-; and











Effector is part of a (i) a phosphoric acid derivative of gemcitabine, or (ii) a salt form of a phosphoric acid derivative of gemcitabine.

7. The compound according to any of the above claims, or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein the linker region (L) is

-C(H)₂-O-C(O)-.

8. The compound according to claim 1 having formulae (Id-i), (Id-ii), (Id-iii), (Id-iv), (Id-v), (Id-vi), (Id-vii), (Id-viii), (Id-ix), (Id-x), (Id-xi), (Id-xii), (Id-xiii), (Id-xiv), (Id-xv), (Id-xvi), (Id-xvii), (Id-xviii), (Id-xix), or (Id-xx):





or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer of any of the above formulae, wherein:

Z^3 , Z^4 , and Z^5 are each independently methyl optionally substituted with 1-3 halo, halo, methoxy optionally substituted with 1-3 halo or deuterated methoxy; and







M^2 is $-O^- Na^+$, $-O^- Et_3NH^+$, $-O^- K^+$, $-O^- NH_4^+$.




9. The compound according to any of the above claims, or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein Z^3 , Z^5 and Z^4 , when present, are each methoxy optionally substituted with 1-3 halo or deuterated methoxy.

10. The compound according to any of the above claims, or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein Z^3 and Z^5 are each independently bromo or fluoro, and Z^4 , when present, is methoxy optionally substituted with 1-3 halo, or deuterated methoxy.

11. The compound according to any of the above claims, or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein the compound is in a sodium phosphate or triethylammonium phosphate salt form thereof.


12. The compound according to claim 1 having one of the following structures:

Compound #	Structure
1	 Et_3NH^+
2	 $\text{Na}_2\text{O}_3\text{PO}$
3	 Et_3NH^+
4	 Et_3NH^+
5	 Et_3NH^+
6	 Et_3NH^+

7	 2 Et ₃ NH ⁺
8	 2 Et ₃ NH ⁺
9	 Et ₃ NH ⁺

or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer of any one of compounds 1-9.

13. The compound according to claim 1, having formula (Id-ii-1)



or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof

wherein:

Z³, Z⁴, and Z⁵ are each independently hydrogen, methyl optionally substituted with 1-3 halo, halo, methoxy optionally substituted with 1-3 halo or deuterated methoxy; and


each M² is independently selected from the group consisting of OH and O⁻ (M¹), wherein (M¹) in each occurrence is independently a metal cation, ammonium, an alkyl ammonium cation, or an amino acid cation.

14. The compound according to claim 13, wherein (M¹) is selected from the group consisting of Na⁺, Ca²⁺, K⁺, Mg²⁺, Zn²⁺, NH⁴⁺, (HNEt₃)⁺, meglumine-H⁺, Tromethamine-H⁺, Diethanolamine-H⁺, lysine-H⁺, and arginine-H⁺.

15. The compound according to any one of claims 13-14, wherein each of Z⁵ and Z³ is independently methoxy.

16. The compound according to any one of claims 13-15, wherein Z⁴ is hydrogen.

17. The compound according to any one of claims 13-16, wherein the compound is:



or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof.

18. A composition comprising a compound according to any of the above claims, together with a pharmaceutically acceptable carrier, or pharmaceutically acceptable salt, ester, amide or solvate of a compound according to any of the above claims, together with a pharmaceutically acceptable carrier thereof.

19. A compound, or pharmaceutically acceptable salt, ester, amide or solvate, as defined in any one of claims 1 to 17, for use in medicine.

20. A compound, or pharmaceutically acceptable salt, ester, amide or solvate, as defined in any one of claims 1 to 17, for use in a method of treatment or prophylaxis of a proliferative condition.

21. The compound, or pharmaceutically acceptable salt, ester, amide or solvate, for use in a method of treatment or prophylaxis of claim 20, wherein the proliferative condition is a cancer selected from bladder, brain, breast, colon, head and neck, kidney, lung, liver, ovarian, pancreatic, prostate or skin cancer.

22. Use of a compound, or pharmaceutically acceptable salt, ester, amide or solvate, as defined in any one of claims 1 to 21, for the preparation of a medicament for use in a method of treatment or prophylaxis of a proliferative condition.

23. A method of diagnosis of a patient for the presence of tumor cells expressing the CYP1B1 enzyme comprising (a) administering to the patient a specific compound according to any of claims 1-21, (b) determining the amount of corresponding hydroxylated metabolite which is subsequently produced; and, (c) correlating the amount with the presence or absence of the tumor cells in the patient.

24. A method of (1) identifying the presence of a tumor in a patient; and (2) treating the patient, identified as needing the treatment, by administering a therapeutically or prophylactically useful amount of a compound according to any of claims 1-21, or pharmaceutically acceptable salt, ester, amide or solvate thereof.

25. A method of treating a proliferative condition, said method comprising administering a therapeutically useful amount of a compound of any one of claims 1-21, or pharmaceutically acceptable salt, ester, amide or solvate thereof, to a subject in need thereof.